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Background: We investigated the effects of gene polymorphisms on the develop-
ment of IgA nephropathy and thin glomerular basement membrane (GBM) disease
by analyzing polymorphisms in the interleukin (IL)-18, transforming growth factor
(TGF)-b, and vascular endothelial growth factor (VEGF) genes in Korean patients.
Methods: This study included 146 normal individuals and 69 biopsy-proven IgA
nephropathy and 44 thin GBM disease patients. The gene polymorphisms 607 A/C
and 137 G/C in IL-18, 509C/T and T869C in TGF-b, and 2578C/A and 405C/G in
VEGF were investigated in DNA extracted from peripheral blood.
Results: The frequencies of the IL-18 607CC genotype (43.5% vs. 21.2%, P¼0.002,
P corrected¼0.012) and the VEGF 405 GG genotype (37.7% vs. 21.2%, P¼0.002,
P corrected¼0.012) were signiﬁcantly increased in the IgA nephropathy group
compared with the control group, whereas no signiﬁcant differences in genotype
frequency were observed between the thin GBM disease and control groups. However,
there were no signiﬁcant differences in genotype and allele frequencies between the
IgA nephropathy and thin GBM disease groups.
Conclusion: This study did not show any statistically signiﬁcant differences of six
selected gene polymorphisms of the IL-18, TGF-b, and VEGF genes between IgA
nephropathy and thin GBM disease. Additional extensive studies are required to
clarify the potential role of gene polymorphism to discriminate IgA nephropathy and
thin GBM disease without renal biopsy.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
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IgA nephropathy and thin glomerular basement membrane
(GBM) disease are representative glomerular diseases that
cause asymptomatic hematuria [1]. Clinical progress of
IgA nephropathy takes diverse forms ranging from reach-
ing the clinical remission stage without treatment to the
development of the terminal stage of renal failure. It wasublished by Elsevier. This is an open access article under the CC BY-NC-
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patients reached the ﬁnal stage of renal failure within 30
years [2]. Some of the patients with thin GBM disease were
reported to have developed renal failure [3], but the prognosis
is generally favorable [4]. Therefore, differential diagnosis of
IgA nephropathy and thin GBM disease is an important part of
determining the treatment method in patients with asympto-
matic hematuria.
IgA nephropathy and thin GBM disease are generally diag-
nosed by renal biopsy. A characteristic of IgA nephropathy is
that IgA deposition can be seen in the mesangium area in
immunoﬂuorescence microscopy. Deposition of electro-dense
material in the mesangium or paramesangium areas can also be
seen by electron microscopy [5]. The thickness of the glomerular
basement membrane measured by electron microscopy, the
criterion for the histological diagnosis of thin GBM disease, is
known to be below 200–250 nm in children and below 250–
264 nm in adults [6] depending on the age. Thin GBM disease is
diagnosed when no deposition of immunoglobulin or comple-
ment is shown in immunoﬂuorescence microscopy and there is
a general decrease in the thickness of the GBM in at least 50% of
the capillary loop [4].
The pathogenesis of IgA nephropathy is not clearly known
yet. There are a number of studies that were based on the
assumption that cytokines, control hormones produced dur-
ing the active and effective phases of immunological reactions
that transmit signals between cells [7], have a certain role in
IgA nephropathy, but these reports have diverse results [8,9].
Although the pathogenesis of thin GBM disease is not com-
pletely known yet, genetic abnormalities are suspected since
there is a high tendency for familial association [4].
It has been reported in many studies that the genetic
polymorphisms of interleukin (IL)-18, transforming growth
factor (TGF)-b, and vascular endothelial growth factor (VEGF)
were involved in the development and progression of a
variety of glomerular diseases including IgA nephropathy
[10–16]. However, cytokines are considered to have less effect
on the development of thin GBM disease from a pathogenic
point of view and there has been no study on cytokine gene
polymorphisms. This study investigated the impact of differ-
ent genetic polymorphisms on the development of IgA
nephropathy and thin GBM disease and attempted to evaluate
the potential of this approach for differential diagnosisTable 1. Primer and hybridization probe sequences
Primer Sequence (50-30) Probe
IL-18
–607 A/C F: GTTGATACAGGCCATTAAGATT GAAAGTGTAAAA
R: CCCTAAATATATGTATCCTTAAATTG LCred640-ATGA
–137 G/C F: AGTGGCAGAGGATACGAG TCATGAAATCTT
R: AAGAGATACTCAGAAAGAGGTACA LCred640-GGGG
TGF-b
–509C/T F: GTAAATTGGGGACAGTAAATGTATG TCCATCCCTCAG
R: CTGGGAAACAAGGTAGGAGAA LCred640-GTTG
869 T/C F: ATCTAGGTTATTTCCGTGGGATAC CTGCTGCCGCTG
R: CAGCTCCATGTCGATAGTCTTG LCred640-CCGC
VEGF
–2578C/A F: GAGGCTATGTCAGCTGTAGGTCA ACCCTGGCACGA
R: CCTCCAACTCTCCACATCTTC LC640-GGATAA
405C/G F: TTGCCATTCCCCACTTGAA CGGTCACCCCCA
R: CCGGGGAGGAGGTGGTA LCred640-CACT
F, forward primer; FL, ﬂuorescence; IL-18, interleukin-18; p, phosphoryla
vascular endothelial growth factor.between the two diseases by conducting the test for the
genetic polymorphisms of IL-18, TGF-b, and VEGF in IgA
nephropathy and thin GBM disease patients and normal
individuals.Methods
Patients
This was a case-control, cross-sectional study, performed
in a single center. A total of 113 Korean patients among IgA
nephropathy and thin GBM disease patients who underwent
renal biopsy at the Kyungpook National University Hospital
(Daegu, Korea) agreed to genotyping analysis and were recruited.
The control group consisted of 146 unrelated, healthy Korean
individuals with normal renal function, normotension, no known
medical problems based on a health-screening questionnaire,
and who agreed to genotyping analysis. The controls were
enrolled from the health promotion center of the same institute
as the patients. The present study was approved by the institu-
tional review board of Kyungpook National University Hospital
(KNUH 2011-04-010).
Genomic DNA extraction
Blood samples (3 mL) were collected in ethylenediaminetetra-
acetic acid tubes, and genomic DNA was isolated from 200 mL of
whole blood using the Fujiﬁlm DNA whole blood kit S with the
QuickGene-810 system (Fujiﬁlm, Tokyo, Japan) according to the
manufacturer‘s instructions. The extracted DNA was assessed for
purity, yield, and concentration on a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington, DE, USA).
Purity was monitored by the A260/280 ratio. The DNA was
diluted to 10 ng/mL for a working solution, and the isolated DNA
was stored at 20 1C.
Cytokine gene polymorphism typing
Polymerase chain reaction (PCR) and melting curve ana-
lyses were performed on a LightCycler480 (Roche Diagnostics,
Penzberg, Germany). The primers and hybridization probes
used in this study were designed using available referenceSize (bp) Annealing temp
(1C)
ATTATTACATAAAATTCT- FL 295 49
TGGTATCCGTGTGGCTTG-p
TTCTTCCGTAAAAGT- FL 121 52
CTCTGTGCCTTCCAAAA-p
GTGTCC- FL 216 54
CCCCCTCCTCCCACTGA-p
CTGC FL 326 54
TGCTGTGGCTACTGGTGCTGAC-p
TCTGG- FL 225 66
TCAGACTGACTGGTCCCACTCTTC-p
AAAGCAGGTCAC- FL 327 68
TTGCCCCTGTCCCTTTCG-p
tion; R, reverse primer; TGF-b, transforming growth factor-b; VEGF,
Table 2. Demographic characteristics of IgA nephropathy, thin GBM disease, and normal controls
IgA Thin GBM Normal P
(n¼69) (n¼44) (n¼146)
Age (y) 34.22713.50 33.66714.95 42.40711.73 o0.001
Sex (male:female) 42:27 24:20 29:117 o0.001
Blood urea nitrogen (mg/dl) 14.9875.70 12.3873.11 0.006
Serum creatinine (mg/dl) 0.9270.43 0.7370.16 0.005
Estimated GFR 107.78742.68 125.46737.12 0.026
24-h proteinuria (mg/d) 1059.4871580.17 272.457472.12 0.002
Values are shown as mean7standard deviation.
GBM, glomerular basement membrane; GFR, glomerular ﬁltration rate (calculated using Modiﬁcation of Diet in Renal Disease formula).
Table 3. Cytokine genotype distributions (%) and allele frequencies in the IgA nephropathy and control groups
IL-18 –607A-C polymorphism
A/A A/C C/C Pn A allele C allele Py
IgA 10 (14.5) 29 (42.0) 30 (43.5) 0.355 0.645
(n¼69)
Control 40 (27.4) 75 (51.4) 31 (21.2) 0.002 (0.012) 0.531 0.469 0.001 (0.006)
(n¼146)
Dominant effect (AA vs. ACþCC) 0.037 (0.222) OR 2.226, CI 1.039–4.773
Recessive effect (AAþAC vs. CC) 0.001 (0.006) OR 2.854, CI 1.536–5.302
IL-18 –137G-C polymorphism
G/G G/C C/C Pn G allele C allele Py
IgA 53(76.8) 16 (23.2) 0 (0.0) 0.116 0.884
(n¼69)
Control 111 (76.0) 30 (20.5) 5 (3.4) 0.352 0.863 0.137 0.545
(n¼146)
Dominant effect (GG vs. GCþCC) 0.900 OR 1.044, CI 0.531–2.053
Recessive effect (GGþGC vs. CC) 0.179 OR 0.966, CI 0.937–0.996
TGF-b –509C-T polymorphism
C/C C/T T/T Pn C allele T allele Py
IgA 14 (20.3) 35(50.7) 20 (29.0) 0.457 0.543
(n¼69)
Control 43 (29.5) 63 (43.2) 40 (27.4) 0.347 0.510 0.490 0.298
(n¼146)
Dominant effect (CC vs. CTþTT) 0.155 OR 1.640, CI 0.826–3.257
Recessive effect (CCþCT vs. TT) 0.808 OR 1.082, CI 0.573–2.040
TGF-b 869T-C polymorphism
T/T T/C C/C Pn T allele C allele Py
IgA 12 (17.4) 36 (52.2) 21 (30.4) 0.565 0.435
(n¼69)
Control 43 (29.5) 63 (43.2) 40 (27.4) 0.162 0.510 0.490 0.144
(n¼146)
Dominant effect (TT vs. TCþCC) 0.057 OR 0.504, CI 0.246–1.033
Recessive effect (TTþTC vs. CC) 0.645 OR 0.863, CI 0.460–1.617
VEGF –2578C-A polymorphism
C/C C/A A/A Pn C allele A allele Py
IgA 42 (60.9) 24 (34.8) 3 (4.3) 0.783 0.217
(n¼69)
Control 82 (56.2) 56 (38.4) 8 (5.5) 0.795 0.753 0.247 0.296
(n¼146)
Dominant effect (CC vs. CAþAA) 0.514 OR 1.214, CI 0.677–2.176
Recessive effect (CCþCA vs. AA) 1.000 OR 1.275, CI 0.328–4.964
VEGF 405C-G polymorphism
C/C C/G G/G Pn C allele G allele Py
IgA 11 (15.9) 32 (46.4) 26 (37.7) 0.391 0.609
(n¼69)
Control 41 (28.1) 74 (50.7) 31 (21.2) 0.002 (0.012) 0.534 0.466 0.006 (0.036)
(n¼146)
Dominant effect (CC vs. CGþGG) 0.555 OR 1.188, CI 0.670–2.109
Recessive effect (CCþCG vs. GG) 0.001 (0.006) OR 2.243, CI 1.197–4.203
n Prefers to genotype distribution.
y Prefers to allele frequency; data were analyzed using the Chi-square test or Fisher‘s exact test as appropriate. P-values were Bonferroni corrected
(blank) for multiple testing.
CI, 95% conﬁdence interval; IL-18, interleukin-18; OR, odds ratio TGF-b, transforming growth factor-b; VEGF, vascular endothelial growth factor.
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Germany; Table 1). Real-time PCR was performed as previously
described [11].Statistical analysis
The results are expressed as the mean7standard deviation
or frequencies. The Hardy-Weinberg equilibrium for each poly-
morphism was tested using the Chi-square test. The differences
in allele frequency and genotype distribution between the two
groups were assessed by Chi-square analysis. The odds ratio
(OR) and 95% conﬁdence interval (CI) were calculated. Logistic
regression analysis was used to adjust for signiﬁcantly different
clinical variables. Statistical analyses were performed using SPSSTable 4. Cytokine genotype distributions (%) and allele frequencies in t
logistic regression analysis
IgA nephropathy Control group
(n¼69) (n¼146)
IL-18 –607 A/C
Genotype
AA 10 (14.5%) 40 (27.4)
AC 29 (42.0%) 75 (51.4)
CC 30 (43.5%) 31 (21.2)
Allele
A 49 (35.5) 155 (53.1)
C 89 (64.5) 137 (46.9)
IL-18–137 G/C
Genotype
GG 53 (76.8) 111 (76.0)
GC 16 (23.2) 30 (20.5)
CC 0 (0.0) 5 (3.4)
Allele
G 122 (88.4) 252 (86.3)
C 16 (11.6) 40 (13.7)
TGF-b -509 C/T
Genotype
CC 14 (20.3) 43 (29.5)
CT 35 (50.7) 63 (43.2)
TT 20 (29.0) 40 (27.4)
Allele
C 63 (45.7) 149 (51.0)
T 75 (54.3) 143 (49.0)
TGF-b 869 T/C
Genotype
TT 12 (17.4) 43 (29.5)
TC 36 (52.2) 63 (43.2)
CC 21 (30.4) 40 (27.4)
Allele
T 60 (43.5) 149 (51.0)
C 78 (56.5) 143 (49.0)
VEGF -2578 C/A
Genotype
CC 42 (60.9) 82 (56.2)
CA 24 (34.8) 56 (38.4)
AA 3 (4.3) 8 (5.5)
Allele
C 108 (78.3) 220 (75.3)
A 30 (21.7) 72 (24.7)
VEGF 405C/G
Genotype
CC 11 (15.9) 41 (28.1)
CG 32 (46.4) 74 (50.7)
GG 26 (37.7) 31 (21.2)
Allele
C 54 (39.1) 156 (53.4)
G 84 (60.9) 136 (46.6)
n P-values were Bonferroni corrected (blank) for multiple testing.
CI, conﬁdence interval; IL-18, interleukin-18; TGF-b, transforming growth18.0 for Windows (SPSS Inc., Chicago, IL, USA). A P valueo0.05
was considered signiﬁcant. When multiple comparisons were
involved, corrected P values were calculated for multiple testing
by the Bonferroni method.Results
This study included 146 normal subjects and 69 IgA nephro-
pathy and 44 thin GBM disease patients. The mean age and the
sex ratio were signiﬁcantly different among the groups (Po0.001
and Po0.001, respectively). Signiﬁcant differences between the
IgA nephropathy and thin GBM disease groups were observed
in all of the serum urea nitrogen (15.075.7 mg/dL vs. 12.47
3.1 mg/dL, P¼0.006), serum creatinine (0.9270.43 mg/dL vs.he IgA nephropathy and control groups after age- and sex-adjusted
Pn Odds ratio 95% CI
1
0.387 1.491 0.604–3.684
0.008 (0.048) 3.693 1.400–9.740
1
0.005 (0.030) 1.993 1.237–3.209
1
0.999
0.357 1.460 0.653–3.266
1
0.683 0.865 0.432–1.733
1
0.081 2.108 0.912–4.871
0.172 1.900 0.756–4.773
1
0.167 1.386 0.872–2.204
1
0.070 2.393 0.933–6.141
0.040 2.476 1.040–5.891
1
0.070 1.538 0.966–2.451
1
0.940 1.059 0.243–4.619
0.590 0.827 0.414–1.650
1
0.746 0.914 0.529–1.578
1
0.226 1.727 0.713–4.183
0.010 (0.060) 3.613 1.362–9.585
1
0.008 (0.048) 1.885 1.179–3.015
factor-b; VEGF, vascular endothelial growth factor.
H-Y Jung et al / SNPs in IgAN and thin GBM disease2380.7370.16 mg/dL, P¼0.005), glomerular ﬁltration rate (107.87
42.7 mL/min/1.73m2 vs. 125.5737.1 mL/min/1.73m2, P¼0.026),
and 24-hour proteinuria (1059.571580.2 mg/day vs. 272.57
472.1 mg/day, P¼0.002; Table 2). The genotype frequencies ofTable 5. Cytokine genotype distributions (%) and allele frequencies in
IL-18 –607A-C polymorphism
A/A A/C C/C Pn
Thin GBM 7 (15.9) 23(52.3) 14(31.8)
(n¼44)
Control 40 (27.4) 75 (51.4) 31 (21.2) 0.1
(n¼146)
Dominant effect (AA vs. ACþCC) 0.1
Recessive effect (AAþAC vs. CC) 0.1
IL-18 –137G-C polymorphism
G/G G/C C/C Pn
Thin GBM 32(72.7) 11 (25.0) 1 (2.3)
(n¼44)
Control 111 (76.0) 30 (20.5) 5 (3.4) 0.8
(n¼146)
Dominant effect (GG vs. GCþCC) 0.6
Recessive effect (GGþGC vs. CC) 0.7
TGF-b –509C-T polymorphism
C/C C/T T/T Pn
Thin GBM 12 (27.3) 21 (47.7) 11 (25.0)
(n¼44)
Control 43 (29.5) 63 (43.2) 40 (27.4) 0.8
(n¼146)
Dominant effect (CC vs. CTþTT) 0.7
Recessive effect (CCþCT vs. TT) 0.7
TGF-b 869T-C polymorphism
T/T T/C C/C Pn
Thin GBM 12 (27.3) 21 (47.7) 11 (25.0)
(n¼44)
Control 43 (29.5) 63 (43.2) 40 (27.4) 0.8
(n¼146)
Dominant effect (TT vs. TCþCC) 0.7
Recessive effect (TTþTC vs. CC) 0.7
VEGF –2578C-A polymorphism
C/C C/A A/A Pn
Thin GBM 26 (59.1) 17 (38.6) 1 (2.3)
(n¼44)
Control 82 (56.2) 56 (38.4) 8 (5.5) 0.6
(n¼146)
Dominant effect (CC vs. CAþAA) 0.7
Recessive effect (CCþCA vs. AA) 0.6
VEGF 405C-G polymorphism
C/C C/G G/G Pn
Thin GBM 5 (11.4) 22(50.0) 17 (38.6)
(n¼44)
Control 41 (28.1) 74 (50.7) 31 (21.2) 0.0
(n¼146)
Dominant effect (CC vs. CGþGG) 0.0
Recessive effect (CCþCG vs. GG) 0.0
n P refers to genotype distribution;
y P refers to allele frequency; data were analyzed using the chi-square test o
(blank) for multiple testing.
CI, 95% conﬁdence interval; GBM, glomerular basement membrane; IL-18
VEGF, vascular endothelial growth factor.the patient and control groups did not deviate signiﬁcantly
from the Hardy–Weinberg equilibrium (P40.05).
The frequencies of the IL-18 –607CC genotype showed a
signiﬁcant difference between the IgA nephropathy group andthe thin GBM disease and control groups
A allele C allele Py
0.420 0.580
82 0.531 0.469 0.069
22 OR 1.995, CI 0.822–4.837
48 OR 0.578, CI 0.273–1.221
G allele C allele Py
0.852 0.148
26 0.863 0.137 0.799
57 OR 1.189, CI 0.554–2.555
02 OR 1.525, CI 0.173–13.409
C allele T allele Py
0.511 0.489
66 0.510 0.490 0.986
80 OR 1.113, CI 0.524–2.364
53 OR 1.132, CI 0.522–2.453
T allele C allele Py
0.511 0.489
66 0.510 0.490 0.986
80 OR 1.113, CI 0.524–2.364
53 OR 1.132, CI 0.522–2.453
C allele A allele Py
0.784 0.216
75 0.753 0.247 .555
31 OR 0.887, CI 0.448–1.758
87 OR 2.493, CI 0.303–20.496
C allele G allele Py
0.364 0.636
19 (0.114) 0.534 0.466 0.005 (0.030)
23 (0.138) OR 3.046, CI 1.122–8.267
20 (0.120) OR 0.428, CI 0.207–0.884
r Fisher‘s exact test as appropriate; P-values were Bonferroni corrected
, interleukin-18; OR, odds ratio; TGF-b, transforming growth factor-b;
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The frequency of the –607A/C single nucleotide polymorphism
(SNP) allele in IL-18 was investigated and A:C allele frequency
ratio was 35.5:64.5 in the IgA nephropathy group and
53.1:46.9 in the control group showing a signiﬁcant differenceTable 6. Cytokine genotype distributions (%) and allele frequencies in
IL-18 –607 A-C polymorphism
A/A A/C C/C
IgA 10 (14.5) 29 (42.0) 30 (43.5)
(n¼69)
Thin GBM 7 (15.9) 23(52.3) 14 (31.8)
(n¼44)
Dominant effect (AA vs. ACþCC)
Recessive effect (AAþAC vs. CC)
IL-18 –137 G-C polymorphism
G/G G/C C/C
IgA 53(76.8) 16 (23.2) 0 (0.0)
(n¼69)
Thin GBM 32(72.7) 11 (25.0) 1 (2.3)
(n¼44)
Dominant effect (GG vs. GCþCC)
Recessive effect (GGþGC vs. CC)
TGF-b –509C-T polymorphism
C/C C/T T/T
IgA 14 (20.3) 35(50.7) 20 (29.0)
(n¼69)
Thin GBM 12 (27.3) 21 (47.7) 11 (25.0)
(n¼44)
Dominant effect (CC vs. CTþTT)
Recessive effect (CCþCT vs. TT)
TGF-b 869 T-C polymorphism
T/T T/C C/C
IgA 12 (17.4) 36 (52.2) 21 (30.4)
(n¼69)
Thin GBM 12 (27.3) 21 (47.7) 11 (25.0)
(n¼44)
Dominant effect (TT vs. TCþCC)
Recessive effect (TTþTC vs. CC)
VEGF –2578C-A polymorphism
C/C C/A A/A
IgA 42 (60.9) 24 (34.8) 3 (4.3)
(n¼69)
Thin GBM 26 (59.1) 17 (38.6) 1 (2.3)
(n¼44)
Dominant effect (CC vs. CAþAA)
Recessive effect (CCþCA vs. AA)
VEGF 405C-G polymorphism
C/C C/G G/G
IgA 11 (15.9) 32 (46.4) 26 (37.7)
(n¼69)
Thin GBM 5 (11.4) 22(50.0) 17 (38.6)
(n¼44)
Dominant effect (CC vs. CGþGG)
Recessive effect (CCþCG vs. GG)
n P refers to genotype distribution;
y P refers to allele frequency; data were analyzed using the Chi-square test
CI, 95% conﬁdence interval; GBM, glomerular basement membrane; IL-18
VEGF, vascular endothelial growth factor.between the two groups (P¼0.001, P corrected¼0.006). In the
recessive genetic analysis, the CC genotype was signiﬁcantly
more frequent in the IgA nephropathy group compared to the
control group (43.5% vs. 21.2%, P¼0.001, P corrected¼0.006,
OR¼2.854, 95% CI 1.536–5.302; Table 3). The frequencies ofthe IgA nephropathy and thin GBM groups
Pn A allele C allele Py
0.355 0.645
0.452 0.420 0.580 .324
0.837 OR 0.896, CI 0.314–2.599
0.215 OR 1.648, CI 0.746–3.643
Pn G allele C allele Py
0.116 0.884
0.435 0.852 0.148 0.486
0.624 OR 1.242, CI 0.522–2.958
0.028 OR 1.023, CI 0.978–1.070
Pn C allele T allele Py
0.457 0.543
0.679 0.511 0.489 0.421
0.390 OR 0.679, CI 0.280–1.646
0.643 OR 1.224, CI 0.519–2.888
Pn T allele C allele Py
0.565 0.435
0.445 0.511 0.489 0.260
0.210 OR 0.561, CI 0.226–1.394
0.532 OR 1.313, CI 0.559–3.082
Pn C allele A allele Py
0.783 0.217
0.445 0.784 0.216 0.979
0.210 OR 1.077, CI 0.498–2.329
0.532 OR 3.359, CI 0.379–29.674
Pn C allele G allele Py
0.391 0.609
0.798 0.364 0.636 0.670
0.496 OR 1.479, CI 0.477–4.590
0.919 OR 0.963, CI 0.441–2.091
or Fisher‘s exact test as appropriate.
, interleukin-18; OR, odds ratio; TGF-b, transforming growth factor-b;
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IgA nephropathy group compared with the control group
(37.7% vs. 21.2%, P¼0.002, P corrected¼0.012). Investigation
of the allele frequency of the 405C/G SNP in VEGF showed the
allele ratio of C:G as 39.1:60.9 in the IgA nephropathy group
and 53.4:46.6 in the control group showing a signiﬁcant
difference between the two groups (P¼0.006, P corrected¼
0.036). In the recessive genetic analysis, the GG genotype was
signiﬁcantly more frequent in the IgA nephropathy group
compared to the control group (37.7% vs. 21.2%, P¼0.001, P
corrected¼0.006, OR¼2.243, 95% CI 1.197–4.203). There were
no signiﬁcant differences in the genotype and allele distribu-
tions of the investigated cytokine gene polymorphisms other
than the IL-18 –607A/C and VEGF 405C/G (Table 3). Compara-
tive analysis between the IgA nephropathy group and control
group using age- and sex-adjusted logistic regression analysis
showed a signiﬁcant difference in the genotype and allele
distribution of the –607A/C SNP in IL-18 and in the allele
frequency of the 405C/G SNP in VEGF (Table 4).
The genotype distribution of the 405C/G SNP in VEGF
between the thin GBM disease group and control group showed
a signiﬁcant difference (P¼0.019). However, the difference
became insigniﬁcant after correcting for multiple comparisons
(P corrected¼0.114). Signiﬁcant differences could not be
observed in the analysis of the dominant inheritance and
regressive inheritance of the 405C/G SNP in VEGF. Investigation
of the allele frequency of the 405C/G SNP in VEGF showed the
allele ratio C:G as 36.4:63.6 in the thin GBM disease group and
53.4:46.6 in the control group, showing a signiﬁcant difference
between the two groups (P¼0.005, P corrected¼0.030, Table 5).
However, after age- and sex-adjusted comparative analysis
between the thin GBM disease group and control group using
logistic regression analysis, the genotype distribution and allele
frequency of the 405C/G SNP in VEGF did not show a signiﬁcant
difference (P corrected¼0.126 and 0.114, respectively). There
were no signiﬁcant differences in the genotype and allele
distributions of the investigated cytokine gene polymorphisms
other than VEGF 405C/G.
In the comparison between the IgA nephropathy group and
thin GBM disease group, the genotype distribution and allele
frequency were not signiﬁcantly different and age- and sex-
adjusted results did not show any signiﬁcant differences
(Table 6). When the IgA nephropathy patients were compared
with the thin GBM disease patients according to the level of
proteinuria (o1.0 g/day vs. Z1.0 g/day) or the glomerular
ﬁltration rate (o60 mL/min vs. Z60 mL/min), no signiﬁcant
differences were observed in the genotype distributions of the
investigated cytokine gene polymorphisms (data not shown).Discussion
This study investigated the possible association of IL-18,
TGF-b, and VEGF gene polymorphisms with the development
of IgA nephropathy and thin GBM disease. The polymorphism
in the IL-18 promoter at position –607 is associated with the
development of IgA nephropathy, and the C allele at IL-18 –
607A/C and the G allele at VEGF 405C/G seem to be associated
with the development of IgA nephropathy and may be risk
alleles. However, no signiﬁcant difference in polymorphisms
could be observed between the thin GBM disease group and
control group. Comparison between the IgA nephropathygroup and thin GBM disease group showed no signiﬁcant
difference in genotype distribution.
In a previous study, the associations of serum or urinary
IL-18 levels with the development of glomerulonephritis have
been reported [17,18]. These ﬁndings indicate that IL-18 levels
are associated with the activity and development of idiopathic
nephrotic syndrome. Among the IL-18 polymorphisms, homo-
zygous for C at position –607 and G at position –137 had higher
levels of IL-18 mRNA compared to other genotypes [10].
Although we did not measure the serum or urine IL-18 levels
in the present study, the IL-18 –607CC genotype, which was
related with higher levels of IL-18 mRNA, was signiﬁcantly more
frequent in the IgA nephropathy group. This ﬁnding is in
concordance with previous studies that found that a high
IL-18 level was associated with the development of glomerulo-
nephritis [17,18].
The VEGF levels have been reported to be associated with the
development and progression of glomerulonephritis [19]. The
urinary VEGF level was correlated with baseline serum creatinine
and erythrocyte sedimentation rate in glomerulonephritis
patients. VEGF mRNA expression in peripheral blood mono-
nuclear cells decreased in patients undergoing remission. VEGF
expression analyses showed that the GG genotype at the 405
position of the VEGF promote region produced higher VEGF
transcripts compared to the CC genotype [20]. Therefore, the
VEGF 405GG genotype, which was signiﬁcantly increased in the
IgA patients in our study, might be associated with an increased
risk of developing IgA nephropathy by producing higher VEGF
transcripts than the other genotypes.
In our previous study, IL-18 and VEGF polymorphisms
were associated with development of primary glomerulone-
phritis. In this study, 69% of glomerulonephritis was IgA
nephropathy and the IL-18 –607CC genotype and VEGF
405GG genotype were associated with susceptibility to and
the development of primary glomerulonephritis [11]. These
data might reﬂect some associations between IgA nephro-
pathy and IL-18 and VEGF polymorphisms.
However, our results could not further support that IL-18 and
VEGF may be related to the progression of IgA nephropathy
because no signiﬁcant relationships were observed between
the genotype distributions of IL-18 or VEGF, and the level of
proteinuria or the glomerular ﬁltration rate. Additional studies
measuring serum and urine levels of IL-18 and VEGF and
comparing histological grades are necessary to further clarify
the potential roles of IL-18 and VEGF gene polymorphisms in
the progression of IgA nephropathy.
The association of TGF-b –509CC and 869CC gene poly-
morphisms with IgA nephropathy has been reported in
several studies [12–15]. Taken together with the present
study, TGF-b gene polymorphisms have been reported to be
associated with the susceptibility of IgA nephropathy in some
races, but there is still weak evidence to prove the association
of TGF-b SNPs with IgA nephropathy in Asian populations. It
is necessary to perform further extensive studies in various
races to investigate the contribution of TGF-b SNPs to the
susceptibility of IgA nephropathy.
The pathogenesis of thin GBM disease is known to
be associated with an abnormality in type 4 collagen synthesis
and many COL4A3 and COL4A4 mutations have been reported
[21]. These mutations could cause a glycine substitution inhibit-
ing the formation of the collagen trimer. We hypothesized
that the genetic polymorphisms affecting cytokine expression
would have less effect on the development of thin GBM disease
Kidney Res Clin Pract 31 (2012) 234–241 241than on IgA nephropathy. Comparing between the thin GBM
disease and control groups, no signiﬁcant difference could be
observed in the genotype distributions and allele frequencies.
This suggests that the genetic polymorphisms are not associated
with the development of thin GBM disease. However, there
was also no signiﬁcant difference when the thin GBM disease
group and IgA nephropathy group were compared. Since
this may be due to the small number of thin GBM patients,
further study is necessary that includes larger numbers
of participants and measures cytokine concentrations in the
serum or tissue.
Our study did have some limitations. First, the sample size
of the phenotype groups was relatively small. Additional
extensive studies are required to investigate the potential
roles of cytokine gene polymorphisms to discriminate IgA
nephropathy and thin GBM disease without renal biopsy.
Second, we could not measure the serum or urine cytokine
levels at the time of biopsy and gene expression of cytokines
in peripheral blood mononuclear cells because of the cross-
sectional study design. Further study comparing cytokine
gene polymorphisms and measuring cytokine concentrations
in serum or tissue might help to differentiate these two
disease groups.
In the present study, the –607A/C IL-18 and 405C/G VEGF
polymorphic variants, who might express higher levels of
serum IL-18 and VEGF, had signiﬁcantly higher frequency of
IgA nephropathy compared to the other genotypes. Although
no signiﬁcant difference in the genotype distribution could
be observed between the IgA nephropathy group and thin
GBM disease group, this is the ﬁrst study on the relationship
between the development of thin GBM disease and cytokine
gene polymorphisms.Conﬂict of interest
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